An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.

Guests

  • Gardiner Harris science reporter for "The New York Times" and author of the mystery novel 'Hazard.'
  • Dr. Peter Bach attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.
  • Dr. Carolyn Hendricks a medical oncologist affiliated with Suburban Hospital in Bethesda.
  • William Hubbard former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

“The Anatomy Of Love,” 25 Years Later

Thursday, Feb 11 2016In the early nineties, anthropologist Helen Fisher wrote “The Anatomy of Love: A Natural History of Mating, Marriage, and Why We Stray.” Now she’s back with the latest research on how love affects the brain and how the Internet has changed dating.

Erika Christakis: “The Importance Of Being Little”

Wednesday, Feb 10 2016Walk into a pre-school classroom in America today and Erika Christakis says it’s likely you’ll see some familiar décor: alphabet charts, bar graphs, calendars, and schedules. It’s all part, says the expert in early child education, of a nationwide drive to make sure kids are ready for school at a younger and younger age.

Analysis Of The New Hampshire Primary

Wednesday, Feb 10 2016New Hampshire holds the nation's first primary election. The winners, the losers and what the results could mean for the presidential candidates vying for the Democratic and Republican nominations.